This CDISC Therapeutic Area standard for HIV was developed through the Coalition for Accelerating Standards and Therapies (CFAST) initiative, a partnership of CDISC and the Critical Path Institute (C-Path), with participation from the NIH National Cancer Institute
Enterprise Vocabulary Services (NCI-EVS), the U.S.
This CDISC Therapeutic Area Standard for Vaccines was developed through the Coalition for Accelerating Standards and Therapies (CFAST) initiative, a partnership of CDISC and the Critical Path Institute (C-Path), with participation from the US NIH National Cancer Institute
Enterprise Vocabulary Services (NCI-EVS), the US Food and Drug Administration, TransCelerate, the Japan Pharmaceutical and Medical Devices Agency and additional stakeholders.
This CDISC Therapeutic Area standard was funded with support in part by grant U24FD005243-01 from the US Food and Drug Administration and developed through the Coalition for Accelerating Standards and Therapies (CFAST) initiative, a partnership of CDISC and the Critical Path Institute (C-Path), with participation from the US NIH National Cancer Institute
Enterprise Vocabulary Services (NCI-EVS), FDA, TransCelerate, the Japan Pharmaceutical and Medical Devices Agency and additional stakeholders.